<DOC>
	<DOCNO>NCT00116064</DOCNO>
	<brief_summary>The purpose study evaluate intranasal lorazepam paediatric status epilepticus . This potentially , effective , safe cheap treatment common paediatric medical emergency compare present first line therapy intramuscular paraldehyde .</brief_summary>
	<brief_title>Intranasal Lorazepam Versus Intramuscular Paraldehyde Paediatric Convulsions</brief_title>
	<detailed_description>The ideal first line anticonvulsant agent would one safely easily give primary health care facility . It quick act , minimal cardiorespiratory side effect relatively prolonged effect cheap . No combination drug delivery system fully satisfy criterion . There large publish study evaluate intranasal lorazepam paediatric status epilepticus . Given favourable pharmacokinetics potential practical advantage , wish assess efficacy safety intranasal delivery lorazepam compare intramuscular paraldehyde , exist first line anticonvulsant agent treatment acute seizures child .</detailed_description>
	<mesh_term>Status Epilepticus</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<mesh_term>Paraldehyde</mesh_term>
	<criteria>Children age 2 month 12 year Presenting generalised convulsion Any child receive anticonvulsant agent within 1 hour presentation Seizure stop rapid cool treatment hypoglycaemia Features consistent organophosphate poisoning , hepatic hypertensive encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>intranasal</keyword>
	<keyword>lorazepam</keyword>
	<keyword>paediatric</keyword>
	<keyword>convulsion</keyword>
</DOC>